# A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD

> **NCT07683065** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 150 (estimated)

## Conditions studied

- Plaque Psoriasis
- Metabolic Dysfunction-Associated Steatotic Liver Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07683065
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-08
- **Primary completion:** 2027-01-15
- **Final completion:** 2027-01-15
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07683065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07683065, "A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07683065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*